CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Constellation Pharmaceuticals Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Constellation Pharmaceuticals Inc.
215 First Street
Suite 200
Phone: (617) 714-0555p:617 714-0555 Cambridge, MA  02142-1293  United States Fax: (617) 577-0472f:617 577-0472
This company ceased filing statements with the SEC on 7/26/2021.
As of 5/16/2024, the Company is part of MorphoSys AG, a subsidiary of Novartis AG
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Constellation Pharmaceuticals, Inc. discovers and develops small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders and other diseases. The Company has three clinical-stage oncology development programs: the first program is evaluating a compound, CPI-0610, other program is evaluating a compound, CPI-1205 and CPI-0209 is initiate Phase I clinical trial and targeting solid tumors. CPI-1205 is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. CPI-0610 is a potent and selective small molecule designed to promote anti-tumor activity by selectively inhibiting the function of BET proteins, which are proteins that normally enhance target gene expression. The Company is conducting the ProSTAR trial, which is an open-label Phase Ib/2 clinical trial of CPI-1205 for the treatment of mCRPC in combination with enzalutamide and abiraterone acetate.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202112/31/2020YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Mark A.Goldsmith 59 3/1/2017 6/1/2009
President, Chief Executive Officer, Director JigarRaythatha 44 3/1/2017 3/1/2017
Chief Financial Officer, Senior Vice President, Treasurer EmmaReeve 60 12/1/2017 10/1/2017
7 additional Officers and Directors records available in full report.

Business Names
Business Name
ActiveUS 166413699v.8
Constellation Securities Corporation

General Information
Number of Employees: 154 (As of 2/19/2021)
Outstanding Shares: 47,914,690 (As of 4/30/2021)
Shareholders: 62
Stock Exchange: NASD
Federal Tax Id: 000973343
Fax Number: (617) 577-0472


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 6, 2024